Barrett's oesophagus and oesophageal adenocarcinoma: How does acid interfere with cell proliferation and differentiation?

Gut

Volumn 54, Issue SUPPL. 1, 2005, Pages

  Fitzgerald, R C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HEREDITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL DIFFERENTIATION; CELL DIVISION; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE PROTEINS; METAPLASIA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 14344253639     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.041558     Document Type: Conference Paper

References (57)

1. Jankowski JA, Harrison RF, Perry I, et al. Barrett's metaplasia. Lancet 2000;356:2079-85.
2. Gillen P, Keeling P, Byrne PJ, et al. Implication of duodenogastric reflux in the pathogenesis of Barrett's esophagus. Br J Surg 1988;75:540-3.
3. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex viva differentiation and proliferation model. J Clin Invest 1996;98:2120-8.
4. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
5. Going JJ, Keith WN, Neilson L, et al. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002;50:373-7.
6. Sirieix P, O'Donovan M, Brown J, et al. Surface expression of mini-chromosome maintenance proteins provides a novel method for detecting patients at risk for developing adeacarcinoma in Barrett's oesophagus. Clin Cancer Res 2003;9:2560-6.
7. Vaezi M, Richter J. Role of acid and duodenogastroesophageal reflux in gastro-oesophageal reflux disease. Gastroenterology 1996;111:1192.
8. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg 1998;2:333-41.
9. Stein HJ, Hoeft S, DeMeester TR. Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Surg 1993;105:107-11.
10. Fitzgerald R, Lascar R, Triadafilopoulos G. Barrett's oesophagus, dysplasia and pharmacologica acid suppression. Aliment Pharmacol Ther 2001;15:269-76.
11. Harmon JW, Johnson LF, Maydonovitch CL. Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 1981;26:65-72.
12. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602.
13. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol 2002;3:187-94.
14. Seery JP. Stem cells of the oesophageal epithelium. J Cell Sci 2002;115:1783-9.
15. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
16. Sampliner R, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus. Am J Gastroenterol 2002;97:270-4.
17. Kahaleh M, Laethem J-LV, Nagy N, et al. Long term follow-up and predictive factors in barrett's esophagus treated by argon plasma coagulation and omeprazole. Gastroenterology 2001;120:A2105.
18. Goldstein S, Yang G, Curtis S, et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997;18:2265-70.
19. Li H, Walsh TN, O'Dowd G, et al. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 1992;115:176-81.
20. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-12.
21. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122:689-96.
22. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002;50:451-9.
23. Fitzgerald R, Abdalla S, Onwuegbusi B, et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002;51:316-322.
24. Mann NS, Tsai MF, Nair PK. Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989;84:1494-6.
25. Winters C, Spurling T, Chobanian S, et al. Barrett's esophagus: a prevalent occult complication of gastro-oesophageal reflux disease. Gastroenterology 1987;92:118-24.
26. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for oesophageal adenocarcinoma. New Engl J Med 1999;340:825-32.
27. el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43:327-33.
28. Prach AT, MacDonald TA, Hopwood DA, et al. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997;350:933.
29. Caygill CP, Reed PI, Johnston BJ, et al. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999;11:1355-8.
30. Fletcher J, Wirz A, Young J, et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001;121:775-83.
31. Spechler SJ. Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology 2002;122:1518-20.
32. Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002;122:299-307.
33. Kaur B, Omary M, Triadafilapoulos G. Bile salt-induced cell proliferation in an ex vivo model of Barrett's esophagus is associated with specific PKC isoform modulation. American Journal of Gastrointestinal & Liver Physiology 2000;278:G1000-9.
34. Putney LK, Barber DL. Na-H exchange-dependent increase in intracellular pH times G2/M entry and transition. J Biol Chem 2003;278:44645-9.
35. Fitzgerald R, Omary M, Triadafilopoulos G. Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. American Journal of Physiology 1998;275:G47-G55.
36. Morgan C, Alazawi W, Sirieix P, et al. Immediate and early gene response to in vitro acid exposure in a Barrett's adenocarcinoma cell line [abstract]. Am J Gastroenterol 2004;99:218-24.
37. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
38. Shirvani V, Ouatu-Luscar R, Kaur B, et al. Cyclo-oxygenase 2 expression in Barrett's esophagus and adenocarcinoma. ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96.
39. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. American Journal of Gastrointestinal & Liver Physiology 2002;283:G327-34.
40. Buttar NS, Wang KK, Leantovick O. Chemopreventive potential of selective cyclo-oxygenase 2 inhibition in Barrett's epithelium: an in vitro study. Gastroenterology 2002;122:1101-12.
41. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-72.
42. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:100-9.
43. Ouatu-Luscar R, Fitzgerald R, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gatsroenterology 1999;117:327-35.
44. Umansky M, Yasui W, Hallak A, et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001;20:7987-91.
45. McDonald ML, Trastek VF, Allen MS, et al. Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg. 1996;111:1135-8 (discussion 1139-40)).
46. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
47. Williamson WA, Ellis FH Jr, Gibb SP, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg. 1990;49:537-41 (discussion 541-2)).
48. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121:1286-93.
49. Katzka D, Castell D. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's oesophagus. Gastroenterology 1994;89:989-91.
50. Ouatu-Luscar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalisation of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998;93:711-6.
51. Shrinivasan R, Ramakrishnan A, Katzka D, et al. Effect of maximal acid reflux control on Barrett's esophagus. Am J Gatsroenterol 1999;94:A93.
52. Castell DO. Succesful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastro 1994;89:989-91.
53. Katz PO, Frissora C. The pharmacology and clinical relevance of proton pump inhibitors. Curr Gastroenterol Rep 2002;4:459-62.
54. Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003;124:615-25.
55. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
56. Bosetti C, Talamini R, Franceschi S, et al. Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 2003;88:672-4.
57. Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002;123:60-7.